JP2019142893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142893A5 JP2019142893A5 JP2019071044A JP2019071044A JP2019142893A5 JP 2019142893 A5 JP2019142893 A5 JP 2019142893A5 JP 2019071044 A JP2019071044 A JP 2019071044A JP 2019071044 A JP2019071044 A JP 2019071044A JP 2019142893 A5 JP2019142893 A5 JP 2019142893A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- chemical formula
- compound
- substituted
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 10
- 238000000634 powder X-ray diffraction Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- OACCNUGECQQVLB-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)N=C1Cl OACCNUGECQQVLB-UHFFFAOYSA-N 0.000 description 1
- OHZYHQOMAJWLDY-MAPNCKNWSA-N C[C@H](CC[C@H](C1)NC2=NC(NC(C)(C)C)=[N]=CC2C(N)=O)[C@@H]1O Chemical compound C[C@H](CC[C@H](C1)NC2=NC(NC(C)(C)C)=[N]=CC2C(N)=O)[C@@H]1O OHZYHQOMAJWLDY-MAPNCKNWSA-N 0.000 description 1
- QBBRJRLJWXRSHQ-CKYFFXLPSA-N C[C@H](CC[C@H](C1)Nc2nc(NC(C)(C)C)ncc2C(N)=O)[C@@H]1O Chemical compound C[C@H](CC[C@H](C1)Nc2nc(NC(C)(C)C)ncc2C(N)=O)[C@@H]1O QBBRJRLJWXRSHQ-CKYFFXLPSA-N 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020127493A JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの固体形態、その組成物、及びその使用方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933636P | 2014-01-30 | 2014-01-30 | |
| US61/933,636 | 2014-01-30 | ||
| US201462025161P | 2014-07-16 | 2014-07-16 | |
| US62/025,161 | 2014-07-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549045A Division JP2017504632A (ja) | 2014-01-30 | 2015-01-29 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127493A Division JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの固体形態、その組成物、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019142893A JP2019142893A (ja) | 2019-08-29 |
| JP2019142893A5 true JP2019142893A5 (https=) | 2019-10-17 |
| JP6742466B2 JP6742466B2 (ja) | 2020-08-19 |
Family
ID=53678405
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549045A Pending JP2017504632A (ja) | 2014-01-30 | 2015-01-29 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
| JP2019071044A Active JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
| JP2020127493A Active JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの固体形態、その組成物、及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549045A Pending JP2017504632A (ja) | 2014-01-30 | 2015-01-29 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127493A Active JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの固体形態、その組成物、及びその使用方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (7) | US9365524B2 (https=) |
| EP (2) | EP3099302B1 (https=) |
| JP (3) | JP2017504632A (https=) |
| KR (2) | KR102505677B1 (https=) |
| CN (3) | CN113717109A (https=) |
| AU (2) | AU2015211036B2 (https=) |
| BR (2) | BR112016017776A8 (https=) |
| CA (1) | CA2938187C (https=) |
| CL (1) | CL2016001927A1 (https=) |
| CR (1) | CR20160346A (https=) |
| CY (1) | CY1123267T1 (https=) |
| DK (1) | DK3099302T3 (https=) |
| EA (2) | EA031671B1 (https=) |
| ES (1) | ES2811834T3 (https=) |
| HR (1) | HRP20201244T1 (https=) |
| HU (1) | HUE051266T2 (https=) |
| IL (2) | IL246931B (https=) |
| LT (1) | LT3099302T (https=) |
| MX (3) | MX373804B (https=) |
| MY (1) | MY180020A (https=) |
| NZ (3) | NZ715903A (https=) |
| PE (1) | PE20161437A1 (https=) |
| PH (1) | PH12016501472B1 (https=) |
| PL (1) | PL3099302T3 (https=) |
| PT (1) | PT3099302T (https=) |
| RS (1) | RS60715B1 (https=) |
| SA (1) | SA516371578B1 (https=) |
| SG (1) | SG11201606054SA (https=) |
| SI (1) | SI3099302T1 (https=) |
| SM (1) | SMT202000430T1 (https=) |
| TW (1) | TWI631108B (https=) |
| WO (1) | WO2015116755A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202400031T1 (it) | 2011-04-22 | 2024-03-13 | Signal Pharm Llc | Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| BR112017012795A2 (pt) | 2014-12-16 | 2018-01-02 | Signal Pharmaceuticals, Llc | Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CA3208587A1 (en) | 2015-07-24 | 2017-02-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| CN111934089B (zh) | 2019-05-13 | 2021-10-26 | 华为技术有限公司 | 天线装置及移动终端 |
| CN113698408B (zh) * | 2020-05-22 | 2025-07-25 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH549339A (de) | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
| US5852028A (en) * | 1995-12-18 | 1998-12-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| US5811428A (en) * | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
| AU5107900A (en) | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| WO2000076980A1 (en) | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| JPWO2003082855A1 (ja) | 2002-03-28 | 2005-08-04 | 協和醗酵工業株式会社 | 抗炎症剤 |
| AU2003244098A1 (en) * | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
| ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| AU2003293409A1 (en) * | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
| JPWO2004054617A1 (ja) | 2002-12-13 | 2006-04-20 | 協和醗酵工業株式会社 | 中枢疾患の予防および／または治療剤 |
| ATE440087T1 (de) | 2003-01-30 | 2009-09-15 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| NZ585188A (en) | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| JP2007506746A (ja) | 2003-09-24 | 2007-03-22 | ワイス・ホールディングズ・コーポレイション | 抗癌剤としての５−アリールピリミジン類 |
| WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
| JP2008505910A (ja) | 2004-07-08 | 2008-02-28 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体 |
| EP1796679A1 (en) | 2004-09-10 | 2007-06-20 | Altana Pharma AG | Ciclesonide and syk inhibitor combination and methods of use thereof |
| CA2579017A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Roflumilast and syk inhibitor combination and methods of use thereof |
| JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| ATE542802T1 (de) | 2004-09-30 | 2012-02-15 | Tibotec Pharm Ltd | Hiv-inhibierende 5-substituierte pyrimidine |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| KR20080004488A (ko) | 2005-03-10 | 2008-01-09 | 바이엘 파마슈티칼스 코포레이션 | 과다증식성 장애 치료용 피리미딘 유도체 |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| MX2009000769A (es) | 2006-07-21 | 2009-01-28 | Novartis Ag | Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak. |
| US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| BRPI0810411B8 (pt) | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| WO2008132505A1 (en) | 2007-04-27 | 2008-11-06 | Astrazeneca Ab | N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions |
| EP2183242A2 (en) | 2007-07-16 | 2010-05-12 | AstraZeneca AB | Pyrimidine derivatives 934 |
| CA2693594A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| EA024109B1 (ru) * | 2008-04-16 | 2016-08-31 | Портола Фармасьютиклз, Инк. | Ингибиторы протеинкиназ |
| SG2014015085A (en) | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| NZ588830A (en) | 2008-04-22 | 2012-11-30 | Portola Pharm Inc | Inhibitors of protein kinases |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| JP5644499B2 (ja) | 2008-09-01 | 2014-12-24 | アステラス製薬株式会社 | ２，４−ジアミノピリミジン化合物 |
| MX2011002825A (es) | 2008-09-18 | 2011-04-05 | Astellas Pharma Inc | Compuestos heterociclicos de carboxamida. |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| PL2346988T3 (pl) | 2008-10-31 | 2017-10-31 | Janssen Biotech Inc | Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki |
| WO2010080864A1 (en) | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
| AU2010219097A1 (en) | 2009-01-13 | 2011-08-04 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase |
| CA2749837C (en) | 2009-01-21 | 2017-07-11 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
| AR076550A1 (es) * | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
| SI2428508T1 (sl) * | 2009-05-08 | 2016-04-29 | Astellas Pharma Inc. | Diamino heterociklična karboksamidna spojina |
| WO2010144468A1 (en) | 2009-06-10 | 2010-12-16 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| US20110130415A1 (en) * | 2009-12-01 | 2011-06-02 | Rajinder Singh | Protein kinase c inhibitors and uses thereof |
| EP2595982B1 (en) | 2010-07-21 | 2018-06-13 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US8580805B2 (en) * | 2010-08-31 | 2013-11-12 | Hubert Maehr | Pyrimidine carboxamide derivatives |
| WO2012044936A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
| WO2012045020A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| SMT202400031T1 (it) * | 2011-04-22 | 2024-03-13 | Signal Pharm Llc | Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse |
| ES2658395T3 (es) * | 2012-04-04 | 2018-03-09 | Rigel Pharmaceuticals, Inc. | Inhibidores de proteína cinasa C y usos de los mismos |
| EP2928891B1 (en) * | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2904610A1 (en) * | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| EP3082819B1 (en) * | 2013-12-20 | 2020-06-17 | Signal Pharmaceuticals, LLC | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
| NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| BR112017012795A2 (pt) * | 2014-12-16 | 2018-01-02 | Signal Pharmaceuticals, Llc | Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida |
| WO2016123291A1 (en) * | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
-
2014
- 2014-09-03 NZ NZ715903A patent/NZ715903A/en unknown
-
2015
- 2015-01-29 WO PCT/US2015/013412 patent/WO2015116755A2/en not_active Ceased
- 2015-01-29 CN CN202110386057.XA patent/CN113717109A/zh active Pending
- 2015-01-29 TW TW104103137A patent/TWI631108B/zh active
- 2015-01-29 ES ES15743503T patent/ES2811834T3/es active Active
- 2015-01-29 PE PE2016001300A patent/PE20161437A1/es not_active Application Discontinuation
- 2015-01-29 KR KR1020167023497A patent/KR102505677B1/ko active Active
- 2015-01-29 EA EA201691544A patent/EA031671B1/ru not_active IP Right Cessation
- 2015-01-29 AU AU2015211036A patent/AU2015211036B2/en active Active
- 2015-01-29 MX MX2016009989A patent/MX373804B/es active IP Right Grant
- 2015-01-29 DK DK15743503.3T patent/DK3099302T3/da active
- 2015-01-29 NZ NZ722412A patent/NZ722412A/en unknown
- 2015-01-29 BR BR112016017776A patent/BR112016017776A8/pt not_active Application Discontinuation
- 2015-01-29 EA EA201792281A patent/EA036964B1/ru not_active IP Right Cessation
- 2015-01-29 MX MX2020003173A patent/MX391127B/es unknown
- 2015-01-29 HU HUE15743503A patent/HUE051266T2/hu unknown
- 2015-01-29 EP EP15743503.3A patent/EP3099302B1/en active Active
- 2015-01-29 PL PL15743503T patent/PL3099302T3/pl unknown
- 2015-01-29 SG SG11201606054SA patent/SG11201606054SA/en unknown
- 2015-01-29 KR KR1020227013115A patent/KR102760889B1/ko active Active
- 2015-01-29 SM SM20200430T patent/SMT202000430T1/it unknown
- 2015-01-29 BR BR122020003206-5A patent/BR122020003206B1/pt active IP Right Grant
- 2015-01-29 JP JP2016549045A patent/JP2017504632A/ja active Pending
- 2015-01-29 US US14/608,314 patent/US9365524B2/en active Active
- 2015-01-29 SI SI201531322T patent/SI3099302T1/sl unknown
- 2015-01-29 CN CN202110386098.9A patent/CN113717110A/zh active Pending
- 2015-01-29 MY MYPI2016702761A patent/MY180020A/en unknown
- 2015-01-29 CN CN201580016658.4A patent/CN106163523A/zh active Pending
- 2015-01-29 CA CA2938187A patent/CA2938187C/en active Active
- 2015-01-29 EP EP20178344.6A patent/EP3738954A1/en active Pending
- 2015-01-29 CR CR20160346A patent/CR20160346A/es unknown
- 2015-01-29 PT PT157435033T patent/PT3099302T/pt unknown
- 2015-01-29 LT LTEP15743503.3T patent/LT3099302T/lt unknown
- 2015-01-29 RS RS20200970A patent/RS60715B1/sr unknown
- 2015-01-29 NZ NZ761068A patent/NZ761068A/en unknown
- 2015-01-29 HR HRP20201244TT patent/HRP20201244T1/hr unknown
-
2016
- 2016-05-12 US US15/152,653 patent/US9814713B2/en active Active
- 2016-07-25 IL IL246931A patent/IL246931B/en active IP Right Grant
- 2016-07-26 PH PH12016501472A patent/PH12016501472B1/en unknown
- 2016-07-28 SA SA516371578A patent/SA516371578B1/ar unknown
- 2016-07-29 MX MX2019005715A patent/MX2019005715A/es unknown
- 2016-07-29 CL CL2016001927A patent/CL2016001927A1/es unknown
-
2017
- 2017-10-09 US US15/727,659 patent/US10226461B2/en active Active
-
2019
- 2019-02-04 US US16/266,793 patent/US10517873B2/en active Active
- 2019-04-03 JP JP2019071044A patent/JP6742466B2/ja active Active
- 2019-11-11 US US16/679,592 patent/US11241430B2/en active Active
-
2020
- 2020-03-26 AU AU2020202146A patent/AU2020202146B2/en active Active
- 2020-06-11 IL IL275305A patent/IL275305B/en unknown
- 2020-07-28 JP JP2020127493A patent/JP7317768B2/ja active Active
- 2020-08-12 CY CY20201100757T patent/CY1123267T1/el unknown
-
2021
- 2021-12-27 US US17/562,933 patent/US20220378785A1/en not_active Abandoned
-
2024
- 2024-06-26 US US18/754,494 patent/US20250000860A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142893A5 (https=) | ||
| JP2014521726A5 (https=) | ||
| RU2016123382A (ru) | Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения | |
| KR20210100094A (ko) | 피리다지논 화합물 및 이의 용도 | |
| JP2020511461A5 (https=) | ||
| JP2012521994A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| JP2013516473A5 (https=) | ||
| EP3752497B1 (en) | P300/cbp hat inhibitors | |
| CA2654313A1 (en) | Aryl-substituted heterobicyclic compounds and their use | |
| JP2019527724A5 (https=) | ||
| AU2015338946B2 (en) | Potent gamma-secretase modulators | |
| CA2654315A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use | |
| RU2019123404A (ru) | Производное пиримидина | |
| JP2013544854A5 (https=) | ||
| BR112014032229B1 (pt) | método para produzir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3- il]piridina-2-carbonitrila | |
| JP2006151999A5 (https=) | ||
| WO2022006427A1 (en) | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat | |
| CA2626402A1 (en) | Potassium channel inhibitors | |
| JP2013541589A5 (https=) | ||
| CN103044284A (zh) | 香草酸酰腙类衍生物及其制备和用途 | |
| FI3679016T3 (fi) | 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja | |
| RU2017142996A (ru) | Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма | |
| CA3232656A1 (en) | Crystal form of imidazolinone derivative |